ranolazine has been researched along with Ventricular Dysfunction, Left in 15 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 4 (26.67) | 29.6817 |
| 2010's | 11 (73.33) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Aljassim, O; Bonadei, I; Bontempi, L; Curnis, A; D'Aloia, A; Raweh, A; Salghetti, F; Vizzardi, E | 1 |
| Fedida, D; Lin, S; McAfee, D; Pourrier, M; Williams, S | 1 |
| Arcari, A; Arra, C; Campesan, M; Carpi, A; Cipresso, C; Condorelli, G; Coppola, C; De Lorenzo, C; Di Lisa, F; Maurea, N; Monti, MG; Piscopo, G; Quintavalle, C; Rea, D; Tocchetti, CG | 1 |
| Canovi, M; Fumagalli, F; Gobbi, M; Latini, R; Letizia, T; Li, Y; Masson, S; Novelli, D; Ristagno, G; Rocchetti, M; Russo, I; Staszewsky, L; Veglianese, P; Zaza, A | 1 |
| Bairey Merz, CN; Berman, DS; Cook-Wiens, G; Handberg, EM; Li, D; Mehta, PK; Nelson, MD; Pepine, CJ; Sharif, B; Shaw, JL; Shufelt, C; Thompson, RB; Thomson, LEJ; Wei, J | 1 |
| Bargelli, V; Bartolucci, G; Belardinelli, L; Cerbai, E; Coppini, R; Crocini, C; Ferrantini, C; Gentile, F; Laurino, A; Mazzoni, L; Mugelli, A; Olivotto, I; Pioner, JM; Poggesi, C; Rotellini, M; Sacconi, L; Santini, L; Tardiff, J; Tesi, C | 1 |
| Belardinelli, L; Blackburn, B; Gupta, RC; Mishra, S; Rastogi, S; Sabbah, HN; Sharov, VG; Stanley, WC | 1 |
| Figueredo, VM; Holderbach, P; Morris, DL; Murdock, E; Pressman, GS; Romero-Corral, A | 1 |
| Belardinelli, L; Dudley, SC; Gu, L; Jeong, EM; Kumar, P; Lardin, HA; Liu, H; Lovelock, JD; Monasky, MM; Patel, BG; Pokhrel, N; Solaro, RJ; Sorescu, D; Taglieri, DM; Zeng, D | 1 |
| Carter, CC; Clanachan, AS; Fatehi, M; Hamming, KS; Light, PE; Soliman, D; Wang, L; Yang, W | 1 |
| Belardinelli, L; Chen, J; Garcia, EV; Hage, FG; Heo, J; Iskandrian, AE; Venkataraman, R | 1 |
| Saklani, P; Skanes, A | 1 |
| Blackburn, B; Chandler, MP; Morita, H; Roth, BA; Sabbah, HN; Stanley, WC; Suzuki, G; Wolff, A | 1 |
| Biesiadecki, BJ; Blackburn, B; Chandler, MP; Chaudhry, P; Mishima, T; Nass, O; Sabbah, HN; Stanley, WC; Suzuki, G; Wolff, A | 1 |
| Belardinelli, L; Sabbah, HN; Undrovinas, AI; Undrovinas, NA | 1 |
1 review(s) available for ranolazine and Ventricular Dysfunction, Left
| Article | Year |
|---|---|
Novel anti-arrhythmic medications in the treatment of atrial fibrillation.
Topics: Acetanilides; Amiodarone; Anisoles; Anti-Arrhythmia Agents; Atrial Fibrillation; Clinical Trials as Topic; Digoxin; Dronedarone; Forecasting; Heart Failure; Humans; Phenethylamines; Piperazines; Pyrrolidines; Ranolazine; Sulfonamides; Technology, Pharmaceutical; Ventricular Dysfunction, Left | 2012 |
2 trial(s) available for ranolazine and Ventricular Dysfunction, Left
| Article | Year |
|---|---|
Improvement in left ventricular systolic and diastolic performance during ranolazine treatment in patients with stable angina.
Topics: Acetanilides; Administration, Oral; Aged; Aged, 80 and over; Angina Pectoris; Black or African American; Echocardiography, Doppler; Enzyme Inhibitors; Female; Follow-Up Studies; Humans; Male; Middle Aged; Piperazines; Ranolazine; Ventricular Dysfunction, Left | 2011 |
Effect of ranolazine on left ventricular dyssynchrony in patients with coronary artery disease.
Topics: Acetanilides; Aged; Coronary Artery Disease; Enzyme Inhibitors; Exercise Test; Female; Follow-Up Studies; Gated Blood-Pool Imaging; Humans; Male; Piperazines; Ranolazine; Tomography, Emission-Computed, Single-Photon; Treatment Outcome; Ventricular Dysfunction, Left | 2012 |
12 other study(ies) available for ranolazine and Ventricular Dysfunction, Left
| Article | Year |
|---|---|
Efficacy of ranolazine in a patient with idiopathic dilated cardiomyopathy and electrical storm.
Topics: Acetanilides; Aged; Anti-Arrhythmia Agents; Cardiomyopathy, Dilated; Defibrillators, Implantable; Electrocardiography; Heart Rate; Humans; Male; Piperazines; Ranolazine; Tachycardia, Ventricular; Treatment Outcome; Ventricular Dysfunction, Left | 2013 |
Ranolazine improves diastolic function in spontaneously hypertensive rats.
Topics: Acetanilides; Aging; Animals; Blood Pressure; Calcium; Cells, Cultured; Diastole; Disease Models, Animal; Dobutamine; Enzyme Inhibitors; Hypertension; In Vitro Techniques; Male; Myocytes, Cardiac; Piperazines; Ranolazine; Rats; Rats, Inbred SHR; Rats, Inbred WKY; Tetrodotoxin; Ventricular Dysfunction, Left | 2014 |
Ranolazine protects from doxorubicin-induced oxidative stress and cardiac dysfunction.
Topics: Acetanilides; Animals; Antibiotics, Antineoplastic; Atrial Natriuretic Factor; Blotting, Western; Cardiotoxicity; Connective Tissue Growth Factor; Doxorubicin; Enzyme Inhibitors; Matrix Metalloproteinase 2; Mice; Mice, Inbred C57BL; Myocytes, Cardiac; Natriuretic Peptide, Brain; Oxidative Stress; Piperazines; Poly(ADP-ribose) Polymerases; Ranolazine; Reactive Oxygen Species; Real-Time Polymerase Chain Reaction; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Sodium; Ultrasonography; Ventricular Dysfunction, Left | 2014 |
Ranolazine ameliorates postresuscitation electrical instability and myocardial dysfunction and improves survival with good neurologic recovery in a rat model of cardiac arrest.
Topics: Acetanilides; Animals; Cardiomyopathies; Cardiopulmonary Resuscitation; Central Nervous System; Disease Models, Animal; Enzyme Inhibitors; Heart Arrest; Piperazines; Ranolazine; Rats; Rats, Sprague-Dawley; Sodium Channel Blockers; Treatment Outcome; Ventricular Dysfunction, Left | 2014 |
Myocardial tissue deformation is reduced in subjects with coronary microvascular dysfunction but not rescued by treatment with ranolazine.
Topics: Adult; Aged; Cardiovascular Agents; Clinical Trials as Topic; Coronary Artery Disease; Coronary Circulation; Coronary Vessels; Diastole; Female; Humans; Magnetic Resonance Imaging, Cine; Male; Microcirculation; Microvessels; Middle Aged; Myocardium; Ranolazine; Retrospective Studies; Sodium Channel Blockers; Stroke Volume; Time Factors; Treatment Outcome; Ventricular Dysfunction, Left; Ventricular Function, Left | 2017 |
Ranolazine Prevents Phenotype Development in a Mouse Model of Hypertrophic Cardiomyopathy.
Topics: Animals; Blotting, Western; Calcium-Calmodulin-Dependent Protein Kinases; Cardiomyopathy, Hypertrophic; Disease Models, Animal; Echocardiography, Doppler; Excitation Contraction Coupling; Genetic Predisposition to Disease; Heart Rate; Hypertrophy, Left Ventricular; Magnetic Resonance Imaging; Male; Membrane Potentials; Mice, Inbred C57BL; Mice, Transgenic; Microscopy, Confocal; Mutation; Myocardial Contraction; Myocytes, Cardiac; Phenotype; Ranolazine; Sodium; Sodium Channel Blockers; Time Factors; Troponin T; Ventricular Dysfunction, Left; Ventricular Function, Left | 2017 |
Ranolazine combined with enalapril or metoprolol prevents progressive LV dysfunction and remodeling in dogs with moderate heart failure.
Topics: Acetanilides; Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Animals; Cardiotonic Agents; Disease Models, Animal; Disease Progression; Dogs; Drug Therapy, Combination; Enalapril; Heart Failure; Metoprolol; Myocardium; Piperazines; Proteins; Ranolazine; Ventricular Dysfunction, Left; Ventricular Remodeling | 2008 |
Ranolazine improves cardiac diastolic dysfunction through modulation of myofilament calcium sensitivity.
Topics: Acetanilides; Animals; Calcium; Desoxycorticosterone; Diastole; Disease Models, Animal; Enzyme Inhibitors; Heart Failure, Diastolic; Mice; Mineralocorticoids; Myocardial Contraction; Myocytes, Cardiac; Myofibrils; Oxidative Stress; Piperazines; Ranolazine; Sodium; Ventricular Dysfunction, Left | 2012 |
Late sodium current inhibition alone with ranolazine is sufficient to reduce ischemia- and cardiac glycoside-induced calcium overload and contractile dysfunction mediated by reverse-mode sodium/calcium exchange.
Topics: Acetanilides; Animals; Animals, Newborn; Calcium; Calcium Signaling; Cardiac Glycosides; Electrophysiological Phenomena; Enzyme Inhibitors; In Vitro Techniques; Ischemia; Lidocaine; Male; Myocardial Contraction; Myocardial Reperfusion Injury; Patch-Clamp Techniques; Piperazines; Ranolazine; Rats; Rats, Sprague-Dawley; Sodium Channel Blockers; Sodium-Calcium Exchanger; Transfection; Ventricular Dysfunction, Left | 2012 |
Short-term treatment with ranolazine improves mechanical efficiency in dogs with chronic heart failure.
Topics: Acetanilides; Animals; Cardiotonic Agents; Chronic Disease; Coronary Circulation; Disease Models, Animal; Dobutamine; Dogs; Drug Administration Schedule; Fatty Acids, Nonesterified; Glucose; Heart; Heart Failure; Heart Rate; Lactic Acid; Myocardium; Oxygen Consumption; Piperazines; Ranolazine; Stroke Volume; Time Factors; Treatment Outcome; Ventricular Dysfunction, Left | 2002 |
Ranolazine, a partial fatty acid oxidation (pFOX) inhibitor, improves left ventricular function in dogs with chronic heart failure.
Topics: 3-Hydroxyacyl CoA Dehydrogenases; Acetanilides; Acetyl-CoA C-Acyltransferase; Animals; Carbon-Carbon Double Bond Isomerases; Chronic Disease; Disease Models, Animal; Dogs; Enoyl-CoA Hydratase; Enzyme Inhibitors; Heart Failure; Heart Ventricles; Hemodynamics; Injections, Intravenous; Models, Cardiovascular; Piperazines; Racemases and Epimerases; Radiography; Ranolazine; Stroke Volume; Ventricular Dysfunction, Left; Ventricular Function, Left | 2002 |
Ranolazine improves abnormal repolarization and contraction in left ventricular myocytes of dogs with heart failure by inhibiting late sodium current.
Topics: Acetanilides; Action Potentials; Animals; Disease Models, Animal; Dogs; Dose-Response Relationship, Drug; Enzyme Inhibitors; Heart Failure; Heart Ventricles; Ion Channel Gating; Membrane Potentials; Myocardial Contraction; Myocytes, Cardiac; Piperazines; Ranolazine; Sodium; Sodium Channels; Ventricular Dysfunction, Left | 2006 |